Assembly Biosciences, Inc. (ASMB) News
Follow Assembly Biosciences, Inc. (ASMB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Assembly Biosciences to present at H.C. Wainwright 28th Annual conference
Assembly Biosciences, Inc. (NASDAQ:ASMB) said senior management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference.
EQUITY | Sep 10, 2026, 08:21 PM UTC
L
Assembly Biosciences to present at H.C. Wainwright conference
EQUITY | Sep 10, 2026, 08:15 PM UTC
L
Assembly Biosciences exercises profit-share option for herpes program
Assembly Biosciences exercised a profit-sharing option under its collaboration with Gilead Sciences for a herpes treatment. It will share 40% of U.S. development costs and profits for the program.
EQUITY | Sep 08, 2026, 08:49 PM UTC
M
ASMB exercises U.S. profit-share option with Gilead
Assembly Biosciences (ASMB) exercised a U.S. profit-share option with Gilead for its HSV helicase-primase inhibitor program.
EQUITY | Sep 08, 2026, 08:00 PM UTC
L
Mizuho cuts Assembly Biosciences price target to $45
Mizuho cut its price target on Assembly Biosciences to $45.00 per share from $53.00, according to Benzinga data.
EQUITY | Sep 01, 2026, 02:59 PM UTC
L
UBS sets $52 price target for Assembly Biosciences
UBS announced a $52.00/Share price target for Assembly Biosciences.
EQUITY | Sep 01, 2026, 01:05 PM UTC
L
Assembly Biosciences reports Q2 2026 financial results and updates
Assembly Biosciences (ASMB) reports its second quarter 2026 financial results and recent updates, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:00 PM UTC